Tolero Pharmaceuticals Home
Making Meaningful Medicines
Tolero Pharmaceuticals, Inc.,
a clinical-stage company, is developing treatments to improve and extend the lives of patients with serious hematological diseases.
clear space
Tolero Pharmaceuticals Presents Positive Preclinical Data that Inhibition of AXL Kinase Restores Tumor Response to Retinoic Acid Line Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia... Line Tolero Pharmaceuticals to Present Preclinical Pipeline Data at the 20th Congress of European Hematology... Line Tolero Pharmaceuticals and Eutropics Announce Results Demonstrating the Predictive Potential of a Biomarker...

Tolero Pharmaceuticals

Tolero PharmaceuticalsTolero Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to alleviating human suffering through the discovery and development of novel therapeutics to treat cancer and other serious human diseases. Our pipeline targets important biological drivers of blood disorders to treat leukemias and anemia. MORE
Learn how Tolero researchers are actively expanding scientific understanding of hematological disease. MORE
See how clinical trials on the use of Alvocidib to treat acute myeloid leukemia (AML) are demonstrating promising results. MORE
Find out how Tolero's pipeline agents offer tremendous opportunities for investors. MORE
clear space